


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

CHANGE OF EXECUTIVE DIRECTOR, JOINT COMPANY SECRETARY AND PROCESS AGENT

Upon the announcement issued on 16 August 2022 by Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) announcing that the Group intends to set its overall organizational structure as the dual organizational structure comprising the headquarters of the Group and the business platform headquarters, and that the two major biopharmaceutical segments of the Company, namely Xuanzhu Biopharmaceutical Technology Co., Ltd. and Jilin Huisheng Biopharmaceutical Co., Ltd. will establish their respective business platform headquarters, the board of directors (the “**Board**”) of the Company hereby announces that, in order to accelerate the upgrade and development of the Company’s pharmaceutical business towards innovative drugs, as well as further enhance and optimize corporate governance in innovative drug segment, the following changes will be implemented on the management personnel of the Company:

1. Resignation of Executive Director, Joint Company Secretary and Process Agent

Mr. Choi Yiau Chong (“**Mr. Choi**”) intends to serve as a senior management in the headquarters of other business platforms of the Group and continues serving the Group with his rich professional experience, to implement the adjustment on the Group’s organizational structure and accelerate the update and development of business. Mr. Choi will resign as an executive director of the Company, and cease to serve as the chairman of the risk management committee (the “**Risk Management Committee**”), a joint company secretary and an authorised representative for the acceptance of service of process and notices on the Company’s behalf in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) of the Company due to such work rearrangement with effect from 17 October 2022. Meanwhile, Mr. Choi has ceased to serve as the chief financial officer of the Company.

Mr. Choi has confirmed that he has no disagreement with the Board, and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Company would like to express its gratitude to Mr. Choi for his contribution during his tenure of service as the executive director and chief financial officer of the Company.

2. Appointment of Executive Director

Ms. Miao Guili (“**Ms. Miao**”) will be appointed as an executive director of the Company with effect from 17 October 2022. Ms. Miao has also been appointed as the chief financial officer of the Company.

Ms. Miao Guili

Ms. Miao Guili, aged 49, is the deputy chief executive officer and chief investment officer of the Company. Ms. Miao has over 15 years of management and investment experience in the PRC pharmaceutical industry, and had held senior management positions as the general manager, deputy general manager, chief financial officer, etc., respectively, in various well-known enterprises, such as China Resources Pharmaceutical Group Limited (stock code: 3320.HK), Top Spring International Holdings Limited (stock code: 3688.HK) and Edding Group Company Limited (億騰醫藥集團有限公司), for more than 10 years. Ms. Miao obtained a Master of Business Administration from the University of Hong Kong. She is a Chartered Certified Accountant (CA) of the Institute of Singapore Chartered Accountants (ISCA), a fellow member of each of the Association of Chartered Certified Accountants (FCCA), the Chartered Institute of Management Accountants (CIMA) and the Chartered Global Management Accountants (CGMA).

Save as disclosed above, Ms. Miao did not hold any directorship in any listed companies during the past three years.

Ms. Miao is not connected with nor has any relationship with any other directors, senior management or the substantial or controlling shareholders (as respectively defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company.

As at the date of this announcement, Ms. Miao holds beneficial interests in 9,000,000 shares of the Company as defined in Part XV of Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Ms. Miao has entered into a director service agreement with the Company with a term starting from 17 October 2022 to 16 October 2025. Ms. Miao will hold office until the next annual general meeting of the Company and will be subject to retirement by rotation and re-election in accordance with the bye-laws of the Company. The annual remuneration of Ms. Miao amounts to HK\$2,760,000, as well as discretionary bonus and benefits determined by the remuneration committee under the Board on the basis of her work performance from time to time.

Save as disclosed above, there is no other information relating to Ms. Miao that is required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules nor is there any other matter relating to the appointment of Ms. Miao required to be brought to the attention of the shareholders of the Company. The Company would like to extend its welcome to Ms. Miao for her new appointment.

3. Change in the Composition of the Risk Management Committee

Ms. Chen Yanling (“**Ms. Chen**”), the executive director of the Company, will be appointed as the chairman of the Risk Management Committee, and Ms. Miao will be appointed as a member of the Risk Management Committee, with effect from 17 October 2022.

4. Change of Joint Company Secretary and Process Agent

Ms. Chen will be appointed as the joint company secretary and the Process Agent, with effect from 17 October 2022, to succeed Mr. Choi. Ms. Mok Ming Wai (“**Ms. Mok**”), another joint company secretary, will also resign as the joint company secretary and the Process Agent, with effect from 17 October 2022, due to work arrangement, and Mr. Li Kin Wai (“**Mr. Li**”) will succeed Ms. Mok.

Ms. Chen Yanling

Ms. Chen Yanling, aged 44, is the executive director and the person in charge of the secretariat of the Board of the Company and was appointed to the Board on 20 April 2018. Her main responsibilities are to manage all matters on the Board, the daily matters relating to the listing of the Company and matters on the management of the Group in Hong Kong, Macau and overseas companies. She joined the Group in March 2006 and served as an assistant to the Chairman of the Group and the secretary of the Board, and has been serving the Group for 16 years. Prior to joining the Group, she worked as an English translation officer at the information centre of Guangzhou Tourism Bureau in 2001. In 2002, she worked as an assistant to general manager at Yip’s Ink & Chemicals (Zhongshan) Company Ltd. (葉氏油墨(中山)有限公司) and was in charge of the daily management of the general manager’s office as well as planning and promotion. In 2004, she worked as an assistant to the president of Guangzhou Culturecom Company Ltd. (廣州文化傳信有限公司) and was in charge of the daily management of the president’s office, formulation and execution of the budget for planning cost, media resources integration and development, and maintenance, etc.

Mr. Li Kin Wai

Mr. Li Kin Wai is currently a manager of the Corporate Services Division of Tricor Services Limited (“**Tricor**”), an integrated provider offering business, corporate and investor services. Mr. Li has over 10 years of experience in the corporate secretarial field and has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Mr. Li is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute (formerly The Hong Kong Institute of Chartered Secretaries) and The Chartered Governance Institute (formerly The Institute of Chartered Secretaries and Administrators). Mr. Li meets the requirements of company secretary under Rule 3.28 of the Listing Rules.

Having considered Ms. Chen's background and experience, the Company believes that, despite her lack of relevant qualification as, or experience for, a company secretary under Rule 3.28 of the Listing Rules, Ms. Chen is able to perform her duties as the joint company secretary of the Company. Therefore, the Company appoints Mr. Li to serve as its joint company secretary to assist Ms. Chen in obtaining relevant experience required by the Listing Rules. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, an exemption (the "**Exemption**") from strict compliance with Rule 3.28 and Rule 8.17 of the Listing Rules during the first three years commencing from the date when Ms. Chen was appointed as the joint company secretary (the "**Exemption Period**"), with conditions that (i) Ms. Chen shall obtain assistance from Mr. Li during the Exemption Period; and (ii) the Exemption can be revoked if the Company seriously violated the Listing Rules. The Stock Exchange expects that the Company will be able to prove that Ms. Chen has the relevant experience defined in Rule 3.28 of the Listing Rules to perform the duties of company secretary after the expiration of the Exemption Period, thereby no further exemption is needed. The Exemption may be revoked or modified if the Company's situation changed.

The Company would like to express its appreciation to Ms. Mok for her contribution to the Company in the past, and takes this opportunity to extend its welcome to Ms. Chen for her new appointment and Mr. Li for taking up the appointment.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 14 October 2022

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Mr. Choi Yiau Chong and Ms. Chen Yanling; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.